Recent News

• 04.24.2025 - Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
• 04.15.2025 - Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
• 04.14.2025 - Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.20.2025 - Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
• 03.20.2025 - Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
• 03.18.2025 - Stifel 2025 Virtual CNS Forum
• 03.16.2025 - Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
• 03.11.2025 - Kostas Biliouris, Ph.D.
• 03.11.2025 - Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Recent Filings

• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.15.2025 - DEF 14A Other definitive proxy statements
• 04.15.2025 - ARS Annual Report to Security Holders
• 04.15.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.01.2025 - 3 Initial statement of beneficial ownership of securities
• 03.27.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.20.2025 - 8-K Current report
• 03.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.13.2025 - 4 Statement of changes in beneficial ownership of securities